Effects of a polypill (Polycap) on risk factors in middle-aged individuals without cardiovascular disease (TIPS): a phase II, double-blind, randomised trial - PubMed (original) (raw)
Clinical Trial
. 2009 Apr 18;373(9672):1341-51.
doi: 10.1016/S0140-6736(09)60611-5. Epub 2009 Mar 30.
Collaborators
- PMID: 19339045
- DOI: 10.1016/S0140-6736(09)60611-5
Clinical Trial
Effects of a polypill (Polycap) on risk factors in middle-aged individuals without cardiovascular disease (TIPS): a phase II, double-blind, randomised trial
Indian Polycap Study (TIPS) et al. Lancet. 2009.
Abstract
Background: The combination of three blood-pressure-lowering drugs at low doses, with a statin, aspirin, and folic acid (the polypill), could reduce cardiovascular events by more than 80% in healthy individuals. We examined the effect of the Polycap on blood pressure, lipids, heart rate, and urinary thromboxane B2, and assessed its tolerability.
Methods: In a double-blind trial in 50 centres in India, 2053 individuals without cardiovascular disease, aged 45-80 years, and with one risk factor were randomly assigned, by a central secure website, to the Polycap (n=412) consisting of low doses of thiazide (12.5 mg), atenolol (50 mg), ramipril (5 mg), simvastatin (20 mg), and aspirin (100 mg) per day, or to eight other groups, each with about 200 individuals, of aspirin alone, simvastatin alone, hydrochlorthiazide alone, three combinations of the two blood-pressure-lowering drugs, three blood-pressure-lowering drugs alone, or three blood-pressure-lowering drugs plus aspirin. The primary outcomes were LDL for the effect of lipids, blood pressure for antihypertensive drugs, heart rate for the effects of atenolol, urinary 11-dehydrothromboxane B2 for the antiplatelet effects of aspirin, and rates of discontinuation of drugs for safety. Analysis was by intention to treat. This study is registered with ClinicalTrials.gov, number NCT00443794.
Findings: Compared with groups not receiving blood-pressure-lowering drugs, the Polycap reduced systolic blood pressure by 7.4 mm Hg (95% CI 6.1-8.1) and diastolic blood pressure by 5.6 mm Hg (4.7-6.4), which was similar when three blood-pressure-lowering drugs were used, with or without aspirin. Reductions in blood pressure increased with the number of drugs used (2.2/1.3 mm Hg with one drug, 4.7/3.6 mm Hg with two drugs, and 6.3/4.5 mm Hg with three drugs). Polycap reduced LDL cholesterol by 0.70 mmol/L (95% CI 0.62-0.78), which was less than that with simvastatin alone (0.83 mmol/L, 0.72-0.93; p=0.04); both reductions were greater than for groups without simvastatin (p<0.0001). The reductions in heart rate with Polycap and other groups using atenolol were similar (7.0 beats per min), and both were significantly greater than that in groups without atenolol (p<0.0001). The reductions in 11-dehydrothromboxane B2 were similar with the Polycap (283.1 ng/mmol creatinine, 95% CI 229.1-337.0) compared with the three blood-pressure-lowering drugs plus aspirin (350.0 ng/mmol creatinine, 294.6-404.0), and aspirin alone (348.8 ng/mmol creatinine, 277.6-419.9) compared with groups without aspirin. Tolerability of the Polycap was similar to that of other treatments, with no evidence of increasing intolerability with increasing number of active components in one pill.
Interpretation: This Polycap formulation could be conveniently used to reduce multiple risk factors and cardiovascular risk.
Comment in
- Can the polypill save the world from heart disease?
Cannon CP. Cannon CP. Lancet. 2009 Apr 18;373(9672):1313-4. doi: 10.1016/S0140-6736(09)60652-8. Epub 2009 Mar 30. Lancet. 2009. PMID: 19339044 No abstract available. - The Indian Polycap Study (TIPS).
Urquhart J. Urquhart J. Lancet. 2009 Sep 5;374(9692):781-2; author reply 782. doi: 10.1016/S0140-6736(09)61586-5. Lancet. 2009. PMID: 19733773 No abstract available. - The Indian Polycap Study (TIPS).
Safford RE. Safford RE. Lancet. 2009 Sep 5;374(9692):781; author reply 782. doi: 10.1016/S0140-6736(09)61585-3. Lancet. 2009. PMID: 19733774 No abstract available. - The Indian Polycap Study (TIPS).
Wald N, Law M. Wald N, et al. Lancet. 2009 Sep 5;374(9692):781; author reply 782. doi: 10.1016/S0140-6736(09)61584-1. Lancet. 2009. PMID: 19733775 No abstract available.
Similar articles
- Comparison of risk factor reduction and tolerability of a full-dose polypill (with potassium) versus low-dose polypill (polycap) in individuals at high risk of cardiovascular diseases: the Second Indian Polycap Study (TIPS-2) investigators.
Yusuf S, Pais P, Sigamani A, Xavier D, Afzal R, Gao P, Teo KK. Yusuf S, et al. Circ Cardiovasc Qual Outcomes. 2012 Jul 1;5(4):463-71. doi: 10.1161/CIRCOUTCOMES.111.963637. Epub 2012 Jul 10. Circ Cardiovasc Qual Outcomes. 2012. PMID: 22787067 Clinical Trial. - Polypill with or without Aspirin in Persons without Cardiovascular Disease.
Yusuf S, Joseph P, Dans A, Gao P, Teo K, Xavier D, López-Jaramillo P, Yusoff K, Santoso A, Gamra H, Talukder S, Christou C, Girish P, Yeates K, Xavier F, Dagenais G, Rocha C, McCready T, Tyrwhitt J, Bosch J, Pais P; International Polycap Study 3 Investigators. Yusuf S, et al. N Engl J Med. 2021 Jan 21;384(3):216-228. doi: 10.1056/NEJMoa2028220. Epub 2020 Nov 13. N Engl J Med. 2021. PMID: 33186492 Free PMC article. Clinical Trial. - Impact of switching from different treatment regimens to a fixed-dose combination pill (polypill) in patients with cardiovascular disease or similarly high risk.
Lafeber M, Spiering W, Visseren FL, Grobbee DE, Bots ML, Stanton A, Patel A, Prabhakaran D, Webster R, Thom S, Rodgers A; UMPIRE investigators. Lafeber M, et al. Eur J Prev Cardiol. 2017 Jun;24(9):951-961. doi: 10.1177/2047487317695616. Epub 2017 Mar 8. Eur J Prev Cardiol. 2017. PMID: 28436727 Clinical Trial. - A polypill for all? Critical review of the polypill literature for primary prevention of cardiovascular disease and stroke.
Carey KM, Comee MR, Donovan JL, Kanaan AO. Carey KM, et al. Ann Pharmacother. 2012 May;46(5):688-95. doi: 10.1345/aph.1Q621. Epub 2012 May 8. Ann Pharmacother. 2012. PMID: 22570437 Review. - Improving cardiovascular protection: focus on a cardiovascular polypill.
Barrios V, Escobar C. Barrios V, et al. Future Cardiol. 2016 Mar;12(2):181-96. doi: 10.2217/fca.15.80. Epub 2015 Dec 10. Future Cardiol. 2016. PMID: 26652213 Review.
Cited by
- Polypill Strategy in Secondary Cardiovascular Prevention.
De la Rosa A, Arrington K, Desai R, Acharya PC. De la Rosa A, et al. Curr Cardiol Rep. 2024 May;26(5):443-450. doi: 10.1007/s11886-024-02046-1. Epub 2024 Apr 1. Curr Cardiol Rep. 2024. PMID: 38557814 Review. - The Effectiveness of Polypill for the Prevention of Cardiovascular Disease: A Meta-Analysis of Randomized Controlled Trials.
Virk GS, Sharma A, Khan MR, Shah K, Mengar J, Chaudhari SS, Batool S, Saleem F. Virk GS, et al. Cureus. 2023 Oct 14;15(10):e47032. doi: 10.7759/cureus.47032. eCollection 2023 Oct. Cureus. 2023. PMID: 38022292 Free PMC article. Review. - Benefits of the Polypill on Medication Adherence in the Primary and Secondary Prevention of Cardiovascular Disease: A Systematic Review.
Lopez-Lopez JP, Gonzalez AM, Lanza P, Lopez-Jaramillo P. Lopez-Lopez JP, et al. Vasc Health Risk Manag. 2023 Sep 12;19:605-615. doi: 10.2147/VHRM.S421024. eCollection 2023. Vasc Health Risk Manag. 2023. PMID: 37719697 Free PMC article. Review. - Correlation of polypill and blood pressure level: A systematic review of clinical trials.
Omrani H, Bahremand M, Keshavarzi F, Solouki L, Zereshki E. Omrani H, et al. J Educ Health Promot. 2023 May 31;12:171. doi: 10.4103/jehp.jehp_845_22. eCollection 2023. J Educ Health Promot. 2023. PMID: 37404929 Free PMC article. - Polypill for atherosclerotic cardiovascular disease prevention in Haiti: Eligibility estimates in a low-income country.
Yan LD, Rouzier V, Pierre JL, Dade E, Sufra R, Huffman MD, Apollon A, St Preux S, Metz M, Sabwa S, Morisset B, Deschamps M, Pape JW, McNairy ML. Yan LD, et al. Front Epidemiol. 2022;2:925464. doi: 10.3389/fepid.2022.925464. Epub 2022 Jul 14. Front Epidemiol. 2022. PMID: 36816341 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical